Cover Image
市場調查報告書

Genfit SA的產品平台分析

Genfit SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 277778
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
Genfit SA的產品平台分析 Genfit SA - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 38 Pages
簡介

Genfit SA是總公司設立於法國的生物科技企業。特別致力於開發配合肝臟及消化器官系統疾病患者的代謝障礙和發炎等未滿足需求的治療藥,及診斷解決方案。

本報告提供Genfit SA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Genfit SA的基本資料

  • Genfit SA概要
  • 主要資訊
  • 企業資料

Genfit SA:R&D概要

  • 主要的治療範圍

Genfit SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Genfit SA:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Genfit SA:藥物簡介

  • GFT-505
  • TGFTX-3 Program
  • SAN/GFT-2 Program
  • SERX-1
  • TGFTX-1 Program
  • TGFTX-4 Program
  • TGFTX-5 Program

Genfit SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Genfit SA:最新的開發平台情形

Genfit SA:開發暫停中的計劃

Genfit SA:開發中止的開發中產品

  • AVE-0847
  • AVE-8134
  • GFT-14

Genfit SA:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07440CDB

Summary

Global Markets Direct's, 'Genfit SA - Product Pipeline Review - 2015', provides an overview of the Genfit SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genfit SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Genfit SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Genfit SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Genfit SA's pipeline products

Reasons to buy

  • Evaluate Genfit SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Genfit SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Genfit SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Genfit SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genfit SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Genfit SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Genfit SA Snapshot
    • Genfit SA Overview
    • Key Information
    • Key Facts
  • Genfit SA - Research and Development Overview
    • Key Therapeutic Areas
  • Genfit SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Genfit SA - Pipeline Products Glance
    • Genfit SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Genfit SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Genfit SA - Drug Profiles
    • elafibranor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAN/GFT-2 Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TGFTX-3 Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SERX-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TGFTX-1 Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TGFTX-4 Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TGFTX-5 Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Genfit SA - Pipeline Analysis
    • Genfit SA - Pipeline Products by Target
    • Genfit SA - Pipeline Products by Route of Administration
    • Genfit SA - Pipeline Products by Molecule Type
    • Genfit SA - Pipeline Products by Mechanism of Action
  • Genfit SA - Recent Pipeline Updates
  • Genfit SA - Dormant Projects
  • Genfit SA - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AVE-0847
      • AVE-8134
      • GFT-14
  • Genfit SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Genfit SA, Key Information
  • Genfit SA, Key Facts
  • Genfit SA - Pipeline by Indication, 2015
  • Genfit SA - Pipeline by Stage of Development, 2015
  • Genfit SA - Monotherapy Products in Pipeline, 2015
  • Genfit SA - Phase II, 2015
  • Genfit SA - Phase I, 2015
  • Genfit SA - Preclinical, 2015
  • Genfit SA - Discovery, 2015
  • Genfit SA - Pipeline by Target, 2015
  • Genfit SA - Pipeline by Route of Administration, 2015
  • Genfit SA - Pipeline by Molecule Type, 2015
  • Genfit SA - Pipeline Products by Mechanism of Action, 2015
  • Genfit SA - Recent Pipeline Updates, 2015
  • Genfit SA - Dormant Developmental Projects,2015
  • Genfit SA - Discontinued Pipeline Products, 2015
  • Genfit SA, Subsidiaries

List of Figures

  • Genfit SA - Pipeline by Top 10 Indication, 2015
  • Genfit SA - Pipeline by Stage of Development, 2015
  • Genfit SA - Monotherapy Products in Pipeline, 2015
  • Genfit SA - Pipeline by Top 10 Target, 2015
  • Genfit SA - Pipeline by Top 10 Route of Administration, 2015
  • Genfit SA - Pipeline by Top 10 Molecule Type, 2015
  • Genfit SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top